Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of 4 dose levels of Depigoid Birch in allergic rhinitis/rhinoconjunctivitis
2008-008448-26Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Jun 2009
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of depigoid birch in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma (4 arms), sponsored by LETI Pharma. Started Jun 2009; status: completed.
02
Drugs
depigoid birch
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2008-008448-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008448-26.